Abstract
Purpose To our knowledge no population based studies have been done to examine whether long-term exposure to testosterone therapy is associated with an increased risk of high grade prostate cancer. We examined whether exposure to testosterone during a 5-year period was associated with an increased risk of high grade prostate cancer and whether this risk increased in a dose-response fashion with the cumulative number of testosterone injections. Materials and Methods Using SEER (Surveillance, Epidemiology and End Results)-Medicare linked data we identified 52,579 men diagnosed with incident prostate cancer between January 1, 2001 and December 31, 2006 who had a minimum of 5 years continuous enrollment in Medicare before the cancer diagnosis. We excluded patients diagnosed at death or after autopsy, those enrolled in a health maintenance organization in the 60 months before diagnosis and those with unknown tumor grade or tumor stage. In the 5 years before diagnosis 574 men had a history of testosterone use and 51,945 did not. Results On logistic regression adjusting for demographic and clinical characteristics exposure to testosterone therapy was not associated with an increased risk of high grade prostate cancer (OR 0.84, 95% CI 0.67-1.05) or receipt of primary androgen deprivation therapy following diagnosis (OR 0.97, 95% CI 0.74-1.30). In addition the risk of high grade disease did not increase according to the total number of testosterone injections (OR 1.00, 95% CI 0.98-1.01). Conclusions Our finding that testosterone therapy was not associated with an increased risk of high grade prostate cancer may provide important information regarding the risk-benefit assessment for men with testosterone deficiency considering treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1612-1616 |
| Number of pages | 5 |
| Journal | Journal of Urology |
| Volume | 194 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 1 2015 |
Fingerprint
Keywords
- androgens
- neoplasm grade
- prostatic neoplasms
- SEER program
- testosterone
ASJC Scopus subject areas
- Urology
Cite this
Long-term exposure to testosterone therapy and the risk of high grade prostate cancer. / Baillargeon, Jacques; Kuo, Yong Fang; Fang, Xiao; Shahinian, Vahakn B.
In: Journal of Urology, Vol. 194, No. 6, 01.12.2015, p. 1612-1616.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term exposure to testosterone therapy and the risk of high grade prostate cancer
AU - Baillargeon, Jacques
AU - Kuo, Yong Fang
AU - Fang, Xiao
AU - Shahinian, Vahakn B.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Purpose To our knowledge no population based studies have been done to examine whether long-term exposure to testosterone therapy is associated with an increased risk of high grade prostate cancer. We examined whether exposure to testosterone during a 5-year period was associated with an increased risk of high grade prostate cancer and whether this risk increased in a dose-response fashion with the cumulative number of testosterone injections. Materials and Methods Using SEER (Surveillance, Epidemiology and End Results)-Medicare linked data we identified 52,579 men diagnosed with incident prostate cancer between January 1, 2001 and December 31, 2006 who had a minimum of 5 years continuous enrollment in Medicare before the cancer diagnosis. We excluded patients diagnosed at death or after autopsy, those enrolled in a health maintenance organization in the 60 months before diagnosis and those with unknown tumor grade or tumor stage. In the 5 years before diagnosis 574 men had a history of testosterone use and 51,945 did not. Results On logistic regression adjusting for demographic and clinical characteristics exposure to testosterone therapy was not associated with an increased risk of high grade prostate cancer (OR 0.84, 95% CI 0.67-1.05) or receipt of primary androgen deprivation therapy following diagnosis (OR 0.97, 95% CI 0.74-1.30). In addition the risk of high grade disease did not increase according to the total number of testosterone injections (OR 1.00, 95% CI 0.98-1.01). Conclusions Our finding that testosterone therapy was not associated with an increased risk of high grade prostate cancer may provide important information regarding the risk-benefit assessment for men with testosterone deficiency considering treatment.
AB - Purpose To our knowledge no population based studies have been done to examine whether long-term exposure to testosterone therapy is associated with an increased risk of high grade prostate cancer. We examined whether exposure to testosterone during a 5-year period was associated with an increased risk of high grade prostate cancer and whether this risk increased in a dose-response fashion with the cumulative number of testosterone injections. Materials and Methods Using SEER (Surveillance, Epidemiology and End Results)-Medicare linked data we identified 52,579 men diagnosed with incident prostate cancer between January 1, 2001 and December 31, 2006 who had a minimum of 5 years continuous enrollment in Medicare before the cancer diagnosis. We excluded patients diagnosed at death or after autopsy, those enrolled in a health maintenance organization in the 60 months before diagnosis and those with unknown tumor grade or tumor stage. In the 5 years before diagnosis 574 men had a history of testosterone use and 51,945 did not. Results On logistic regression adjusting for demographic and clinical characteristics exposure to testosterone therapy was not associated with an increased risk of high grade prostate cancer (OR 0.84, 95% CI 0.67-1.05) or receipt of primary androgen deprivation therapy following diagnosis (OR 0.97, 95% CI 0.74-1.30). In addition the risk of high grade disease did not increase according to the total number of testosterone injections (OR 1.00, 95% CI 0.98-1.01). Conclusions Our finding that testosterone therapy was not associated with an increased risk of high grade prostate cancer may provide important information regarding the risk-benefit assessment for men with testosterone deficiency considering treatment.
KW - androgens
KW - neoplasm grade
KW - prostatic neoplasms
KW - SEER program
KW - testosterone
UR - http://www.scopus.com/inward/record.url?scp=84943296834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943296834&partnerID=8YFLogxK
U2 - 10.1016/j.juro.2015.05.099
DO - 10.1016/j.juro.2015.05.099
M3 - Article
VL - 194
SP - 1612
EP - 1616
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 6
ER -